Abstract
Given increasing prevalence of multi-drug resistant organisms (MDROs), there is a significant interest in exploring non-antibiotic therapeutic options. We discuss basics of bacteriophage therapy (BT) and its role in the treatment of infections due to MDRO. BT employs lytic viruses to infect and lyse bacterial pathogens and is an emerging treatment strategy for treatment of infections caused by MDROs. We summarize key characteristics that make BT an attractive option against MDROs, discuss recent cases in which BT was successfully used to treat antibiotic recalcitrant infections, and discuss challenges that need to be overcome to make BT a viable clinical strategy. BT is a viable therapeutic option needing further research in order to bring it to clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
